A4250

Phase 2Small molecule

AAlbireo, an Ipsen Company

A4250 is one of 12 small molecule programs targeting Cholestasis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CholestasisActive, not recruiting

CholestasisPhase 2

Active, not recruiting

Competition

Competitive Landscape

15 competitors in Cholestasis

#DrugCompanyPhaseTrials

Intralipid

AstraZeneca

Approved

2 2

Smoflipid

FFresenius

Approved

2 3

Actigall

AbbVie

Phase 2

1 4

Polyene Phosphatidyl Choline

ZZhejiang Hisun Pharmaceutical Co. Ltd.

Approved

1 5

Lynavoy

IIntercept Pharmaceuticals

Phase 3

1 6

Omegaven

UUniversity of California, San Diego

Phase 2

6 7

IC-Green

CCHX Technologies Inc.

Phase 1

1 8

A4250

AAlbireo, an Ipsen Company

Phase 2

1 9

Ursodeoxycholic Acid

Daewoong Pharmaceutical Co. LTD.

Preclinical

3 10

Tauroursodeoxycholic Acid

HHumanitas Mirasole SpA

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Fed1 trial

Study of A4250 in Healthy Volunteers Under Fasting, Fed and Sprinkled Conditions

Completed·AAlbireo·Phase 1·NCT03608319·17 enrolled

Cholestasis1 trial

A4250, an IBAT Inhibitor in Pediatric Cholestasis

Completed·AAlbireo·Phase 2·NCT02630875·24 enrolled

Pruritus1 trial

IBAT Inhibitor A4250 for Cholestatic Pruritus

Terminated·SSahlgrenska University Hospital·Phase 2·NCT02360852·9 enrolled

Efficacy and Safety1 trial

This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2

Completed·AAlbireo·Phase 3·NCT03566238·62 enrolled

Children1 trial

Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC

Completed·AAlbireo, an Ipsen Company·Phase 3·NCT03659916·116 enrolled

1 more indication

Unspecified1 trial

A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384

Completed·AAlbireo·Phase 1·NCT02963077·94 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for A4250. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — A4250 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for A4250. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Albireo, an Ipsen Company company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAlbireo, an Ipsen Company

A4250

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Fed1 trial

Cholestasis1 trial

Pruritus1 trial

Efficacy and Safety1 trial

Children1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News